Summary of Key Points Core Viewpoint - The company plans to use its own funds to pay for investment projects and subsequently replace these funds with raised capital, ensuring efficient use of resources and compliance with regulatory requirements [1][6]. Group 1: Fundraising Overview - The company raised a total of RMB 973.6 million by issuing 40 million shares at RMB 24.34 per share, with a net amount of RMB 891.425937 million after deducting issuance costs [1]. - The funds were deposited into a special account dedicated to the raised capital, adhering to the principle of dedicated use [1]. Group 2: Investment Project Details - As of June 30, 2025, the company has invested RMB 677.7135 million in various projects, including innovative drug research and brand development [2]. - The total committed investment for the projects remains at RMB 891.4259 million, indicating that the company is on track with its financial commitments [2]. Group 3: Reasons for Using Own Funds - The company encountered operational challenges that necessitated the use of its own funds for project payments, primarily due to banking regulations regarding payroll and the need for efficient fund management [3]. - Using own funds initially allows for better management of project costs and compliance with financial regulations, enhancing operational efficiency [3]. Group 4: Replacement Process - The company intends to replace the funds used from its own resources with raised capital within six months, ensuring that the funds are accounted for as part of the investment project [4]. - The replacement process involves transferring equivalent amounts from the special account to the company's own funds account after necessary approvals [4]. Group 5: Impact on Daily Operations - The use of own funds is expected to optimize payment methods for investment projects, improve fund utilization efficiency, and lower financial costs without affecting the company's normal operations [5]. - The decision aligns with the interests of all shareholders and does not alter the intended use of raised funds [5]. Group 6: Approval Procedures - The board of directors and the supervisory board have both approved the proposal to use own funds for project payments, confirming that the decision complies with relevant regulations [6]. - The approval process followed legal and regulatory requirements, ensuring transparency and accountability in the decision-making process [6].
康辰药业: 天风证券股份有限公司关于北京康辰药业股份有限公司使用自有资金支付募投项目所需资金并以募集资金等额置换的核查意见